1. Home
  2. LAW vs CABA Comparison

LAW vs CABA Comparison

Compare LAW & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$4.34

Market Cap

271.7M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.14

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
CABA
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.7M
319.6M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
LAW
CABA
Price
$4.34
$3.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.00
$14.50
AVG Volume (30 Days)
175.6K
1.9M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
22.58
10.26
EPS
N/A
N/A
Revenue
$156,849,000.00
N/A
Revenue This Year
$11.23
N/A
Revenue Next Year
$10.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.29
N/A
52 Week Low
$2.45
$1.11
52 Week High
$9.11
$3.78

Technical Indicators

Market Signals
Indicator
LAW
CABA
Relative Strength Index (RSI) 58.85 51.47
Support Level $3.91 $2.11
Resistance Level $4.69 $3.34
Average True Range (ATR) 0.22 0.22
MACD 0.09 0.01
Stochastic Oscillator 92.89 55.30

Price Performance

Historical Comparison
LAW
CABA

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: